Johnson & Johnson reported a significant decline in Q2 sales and earnings, primarily due to the adverse effects of the COVID-19 pandemic on its Medical Devices segment. Although there are signs of recovery and progress in vaccine development, the downward revision of full-year guidance and ongoing operational challenges suggest short-term headwinds for the stock. Investors may react negatively to the weaker financial performance and cautious outlook.

[-1]